Clinical Trials Browser

Phase EARLY_PHASE1 × Neuromyelitis Optica × 90 days × Clear all

NCT07392528 2026-02-11

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Phase EARLY_PHASE1 Not yet recruiting

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica